NCT00429793View on ClinicalTrials.gov

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Fallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG

temsirolimus

Given IV

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00429793 - Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter